Group 1: Company Overview and Financial Performance - The company plans to distribute a cash dividend of 2 CNY per 10 shares, totaling 25,261,788.40 CNY, based on a total share capital of 126,308,942 shares [1] - The capital reserve will be used to increase share capital by 3 shares for every 10 shares held, resulting in an increase of 37,892,682 shares, bringing the total to 164,201,624 shares [2] - The net profit attributable to shareholders for 2024 decreased by 57.96% due to factors such as fluctuations in downstream demand and increased depreciation expenses [3] Group 2: Profitability and Cost Structure - The overall gross margin for 2024 was 38.79%, down from 41.62% in the previous year, reflecting a decrease of 2.83% [5] - Increased costs were attributed to rising depreciation and amortization expenses due to ongoing investment projects and changes in product structure [5] Group 3: Future Plans and Market Strategy - The company aims to enhance its competitive edge by focusing on new product development, including components for pre-filled syringes and drug delivery systems [6] - A specialized team will be established to advance the drug aluminum cap project, aiming to create an integrated supply chain for rubber stoppers and aluminum caps [6] - The company is considering the possibility of mergers and acquisitions for external expansion, subject to legal and regulatory procedures [6]